Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pascale Tomasini

Showing results (1-10 of 95) with videos related to

Pageof 10
Sort By:
The Lancet. Oncology|April 7, 2020
Non-small-cell lung cancer brain metastases and PD-(L)1 immune checkpoint inhibitorsFabrice Barlesi, Pascale Tomasini
Translational Lung Cancer Research|February 11, 2020
Targeted next-generation sequencing to assess tumor mutation burden: ready for prime-time in non-small cell lung cancer?Pascale Tomasini, Laurent Greillier
Therapeutic Advances in Medical Oncology|February 17, 2018
Atezolizumab: feasible second-line therapy for patients with non-small cell lung cancer? A review of efficacy, safety and place in therapyFanny Jean, Pascale Tomasini, Fabrice Barlesi
Pharmacogenomics and Personalized Medicine|August 25, 2021
The Value of Population Screening in Advancing Personalized Medicine in the Field of Lung CancerAlice Mogenet, Laurent Greillier, Pascale Tomasini
Expert Opinion on Biological Therapy|June 9, 2015
Necitumumab for non-small cell lung cancerLaurent Greillier, Pascale Tomasini, Fabrice Barlesi
Annals of Translational Medicine|July 19, 2016
Elderly selection on geriatric index assessmentPascale Tomasini, Celine Mascaux, Fabrice Barlesi
Translational Lung Cancer Research|November 7, 2024
Predictive biomarkers for immune checkpoint efficacy: is multi-omics breaking the deadlock?Alice Mogenet, Laurent Greillier, Pascale Tomasini
Therapeutic Advances in Respiratory Disease|June 25, 2016
Bevacizumab in the treatment of nonsquamous non-small cell lung cancer: clinical trial evidence and experienceLaurent Greillier, Pascale Tomasini, Fabrice Barlesi
Translational Lung Cancer Research|December 4, 2018
The clinical utility of tumor mutational burden in non-small cell lung cancerLaurent Greillier, Pascale Tomasini, Fabrice Barlesi
Expert Review of Anticancer Therapy|July 14, 2022
Nivolumab plus ipilimumab in malignant pleural mesotheliomaCamille Travert, Pascale Tomasini, Laurent Greillier
Pageof 10

Showing results (1-10 of 95) with videos related to

Sort By:
Pageof 10
The Lancet. Oncology|April 7, 2020
Non-small-cell lung cancer brain metastases and PD-(L)1 immune checkpoint inhibitorsFabrice Barlesi, Pascale Tomasini
Translational Lung Cancer Research|February 11, 2020
Targeted next-generation sequencing to assess tumor mutation burden: ready for prime-time in non-small cell lung cancer?Pascale Tomasini, Laurent Greillier
Therapeutic Advances in Medical Oncology|February 17, 2018
Atezolizumab: feasible second-line therapy for patients with non-small cell lung cancer? A review of efficacy, safety and place in therapyFanny Jean, Pascale Tomasini, Fabrice Barlesi
Pharmacogenomics and Personalized Medicine|August 25, 2021
The Value of Population Screening in Advancing Personalized Medicine in the Field of Lung CancerAlice Mogenet, Laurent Greillier, Pascale Tomasini
Expert Opinion on Biological Therapy|June 9, 2015
Necitumumab for non-small cell lung cancerLaurent Greillier, Pascale Tomasini, Fabrice Barlesi
Annals of Translational Medicine|July 19, 2016
Elderly selection on geriatric index assessmentPascale Tomasini, Celine Mascaux, Fabrice Barlesi
Translational Lung Cancer Research|November 7, 2024
Predictive biomarkers for immune checkpoint efficacy: is multi-omics breaking the deadlock?Alice Mogenet, Laurent Greillier, Pascale Tomasini
Therapeutic Advances in Respiratory Disease|June 25, 2016
Bevacizumab in the treatment of nonsquamous non-small cell lung cancer: clinical trial evidence and experienceLaurent Greillier, Pascale Tomasini, Fabrice Barlesi
Translational Lung Cancer Research|December 4, 2018
The clinical utility of tumor mutational burden in non-small cell lung cancerLaurent Greillier, Pascale Tomasini, Fabrice Barlesi
Expert Review of Anticancer Therapy|July 14, 2022
Nivolumab plus ipilimumab in malignant pleural mesotheliomaCamille Travert, Pascale Tomasini, Laurent Greillier
Pageof 10